MedTrace Logo

Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy

NCT03065478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2018-09-06

No results posted yet for this study

Summary

The objective of this observational study is to evaluate the effectiveness of the dietary supplementation "OnLife" in improving signs and symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adult patients who have finished adjuvant oxaliplatin-containing regimen (colon cancer) or adjuvant paclitaxel regimen (breast cancer). Furthermore, patient-reported outcomes (PROs) and concomitant medication used for the treatment of neuropathic pain will be assessed.

Conditions

  • CIPN in Adjuvant Colon Cancer Patients
  • CIPN in Adjuvant Breast Cancer Patients

Interventions

DIETARY_SUPPLEMENT

OnLife

Daily dosing of dietary supplement OnLife

Sponsors & Collaborators

  • iOMEDICO AG

    collaborator INDUSTRY

  • Swiss Medical Food AG

    lead INDUSTRY

Principal Investigators

  • Matthias Zaiss, Dr. · Praxis für interdisziplinäre Onkologie & Hämatologie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-22
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065478 on ClinicalTrials.gov